Update on the pathophysiology of liver fibrosis

Expert Review of Gastroenterology and Hepatology

Volumn 4, Issue 4, 2010, Pages 459-472

  Pinzani, Massimo ^a   MacIas Barragan, Jose ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

adipokines; angiogenesis; cannabinoid system; chronic wound healing; cirrhosis; innate immunity; liver fibrosis; macrophages; myofibroblast; oxidative stress; viral proteins

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; ADIPOCYTOKINE; ADIPONECTIN; ANGIOTENSIN II; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID 2 RECEPTOR; CHEMOKINE RECEPTOR CCR2; INTERCELLULAR ADHESION MOLECULE 1; LEPTIN; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; NONSTRUCTURAL PROTEIN 3; RESISTIN; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; VASCULOTROPIN; VIRUS PROTEIN;

CELL DAMAGE; CELL PROLIFERATION; CELL SURVIVAL; CELL TYPE; CHRONIC LIVER DISEASE; DENDRITIC CELL; DISEASE ASSOCIATION; DISEASE COURSE; DRUG MECHANISM; FIBROGENESIS; HUMAN; INNATE IMMUNITY; LIVER CIRRHOSIS; LIVER FIBROSIS; MACROPHAGE FUNCTION; MOLECULAR DYNAMICS; MYOFIBROBLAST; NATURAL KILLER CELL; NATURAL KILLER T CELL; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; REVIEW; WOUND HEALING;

HUMANS; LIVER; LIVER CIRRHOSIS; SIGNAL TRANSDUCTION;

EID: 77955249005     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/egh.10.47     Document Type: Review

References (117)

1. Poynard T, Bedossa P, Opolon P. Natural history of liver fbrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 349, 825-832 (1997).
2. Pinzani M, Rombouts K. Liver fbrosis: from the bench to clinical targets. Dig Liver Dis. 36, 231-242 (2004).
3. Friedman SL. Mechanisms of hepatic fbrogenesis. Gastroenterology 134, 1655-1669 (2008).
4. Bataller R, Brenner DA. Liver fbrosis. J. Clin. Invest. 115(2), 209-218 (2005).
5. Wynn TA. Common and unique mechanisms regulate fbrosis in various fbroproliferative diseases. J. Clin. Invest. 117, 524-529 (2007).
6. Wake K. Perisinusoidal stellate cells (fat-storing cells, interstitial cells, lipocytes), their related structure in and around the liver sinusoids, and vitamin A-storing cells in extrahepatic organs. Int. Rev. Cytol. 66, 303-353 (1980).
7. Schuppan D, Ruehl M, Somasundaram R, Hahn EG. Matrix as a modulator of hepatic fbrogenesis. Semin. Liver Dis. 21, 351-372 (2001).
8. Cassiman D, Roskams T. Beauty is in the eye of the beholder: emerging concepts and pitfalls in hepatic stellate cell research. J. Hepatol. 37, 527-535 (2002).
9. Bucala R, Spiegel LA, Chesney J, Hogan M, Cerami A. Circulating fbrocytes defne a new leukocyte subpopulation that mediates tissue repair. Mol. Med. 1, 71-81 (1994).
10. Quan TE, Cowper SE, Bucala R. The role of circulating fbrocytes in fbrosis. Curr. Rheumatol. Rep. 8, 145-150 (2006).
11. Brittan M, Hunt T, Jeffery R et al. Bone marrow derivation of pericryptal myofbroblasts in the mouse and human small intestine and colon. Gut 50, 752-757 (2002).
12. Russo FP, Alison MR, Bigger BW et al. The bone marrow functionally contributes to liver fbrosis. Gastroenterology 130, 1807-1821 (2006).
13. Kisseleva T, Uchinami H, Feirt N et al. Bone marrow-derived fbrocytes participate in pathogenesis of liver fbrosis. J. Hepatol. 45, 429-438 (2006).
14. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fbrosis. J. Clin. Invest. 112, 1776-1784 (2003).
15. Willis BC, du Bois RM, Borok Z. Epithelial origin of myofbroblasts during fbrosis in the lung. Proc. Am. Thorac. Soc. 3, 377-382 (2006).
16. Zeisberg EM, Tarnavski O, Zeisberg M et al. Endothelial-to-mesenchymal transition contributes to cardiac fbrosis. Nat. Med. 13, 952-961 (2007).
17. Choi SS, Diehl AM. Epithelial-to-mesenchymal transition in the liver. Hepatology 50, 2007-2013 (2009).
18. Zeisberg M, Yang C, Martino M et al. Fibroblasts derive from hepatocytes in liver fbrosis via epithelial to mesenchymal transition. J. Biol. Chem. 282, 23337-23347 (2007).
19. Kaimori A, Potter J, Kaimori JY, Wang C, Mezey E, Koteish A. Transforming growth factor-p1 induces an epithelial-to-mesenchymal transition state in mouse hepatocytes in vitro. J. Biol. Chem. 282, 22089-22101 (2007).
20. Omenetti A, Yang L, Li YX et al. Hedgehog-mediated mesenchymal-epithelial interactions modulate hepatic response to bile duct ligation. Lab. Invest. 87, 499-514 (2007).
21. Omenetti A, Porrello A, Jung Y et al. Hedgehog signaling regulates epithelial-mesenchymal transition during biliary fbrosis in rodents and humans. J. Clin. Invest. 118, 3331-3342 (2008).
22. Rygiel KA, Robertson H, Marshall HL et al. Epithelial-mesenchymal transition contributes to portal tract fbrogenesis during human chronic liver disease. Lab. Invest. 88, 112-123 (2008).
23. Taura K, Miura K, Iwaisako K et al. Hepatocytes do not undergo epithelial-mesenchymal transition in liver fbrosis in mice. Hepatology 51, 1027-1036 (2009).
24. Kumar V, Abbas AK, Fausto N. Tissue renewal and repair: regeneration, healing, and fbrosis. In: Pathologic Basis of Disease. Kumar V, Abbas AK, Fausto N (Eds). Elsevier Saunders, PA, USA, 87-118 (2005).
25. Wynn TA. Cellular and molecular mechanisms of fbrosis. J. Pathol. 214, 199-210 (2008).
26. Calvaruso V, Maimone S, Gatt A et al. Coagulation and fbrosis in chronic liver disease. Gut 57, 1722-1727 (2008).
27. Marra F. Chemokines in liver infammation and fbrosis. Front. Biosci. 7, d1899-d1914 (2002).
28. Karlmark KR, Wasmuth HE, Trautwein C, Tacke F. Chemokine-directed immune cell infltration in acute and chronic liver disease. Expert Rev. Gastroenterol. Hepatol 2(2), 233-242 (2008).
29. Bataller R, Schwabe RF, Choi YH et al NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fbrosis. J. Clin. Invest. 112, 1383-1394 (2003).
30. Oakley F, Teoh V, Ching-A-Sue G et al. Angiotensin II activates iicb kinase phosphorylation of RelA at Ser(536) to promote myofbroblast survival and liver fbrosis. Gastroenterology 136, 2334-2344 (2009).
31. Pinzani M. Unraveling the spider web of hepatic stellate cell apoptosis. Gastroenterology 136, 2061-2063 (2009).
32. Novo E, Marra F, Zamara E et al. Over expression of Bcl-2 by activated human hepatic stellate cells: resistance to apoptosis as a mechanism of progressive hepatic fbrogenesis in humans. Gut 55, 1174-1182 (2006).
33. Moreno M, Gonzalo T, Kok RJ et al. Reduction of advanced liver fbrosis by short-term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats. Hepatology 51(3), 942-952 (2010).
34. Novo E, Parola M. Redox mechanisms in hepatic chronic wound healing and fbrogenesis. Fibrogenesis Tissue Repair 1, 5 (2008).
35. Chang CY, Argo CK, Al-Osaimi AM, Caldwell SH. Therapy of NAFLD: antioxidants and cytoprotective agents. J. Clin. Gastroenterol. 40, S51-S60 (2006).
36. De Alwis NMW, Day CP. Non-alcoholic fatty liver: the mist gradually clear. J. Hepatol. 48, S105-S1 12 (2008).
37. Sokol RJ, McKim JM Jr, Goff MC et al. Vitamin E reduces oxidant injury to mitochondria and the hepatotoxicity of taurochenodeoxycholic acid in the rat. Gastroenterology 114(1), 164-174 (1998).
38. Sokol RJ, Dahl R, Devereaux MW, Yerushalmi B, Kobak GE, Gumpricht E. Human hepatic mitochondria generate reactive oxygen species and undergo the permeability transition in response to hydrophobic bile acids. J. Pediatr. Gastroenterol. Nutr. 41(2), 235-243 (2005).
39. Serviddio G, Pereda J, Pallardó FV et al. Ursodeoxycholic acid protects against secondary biliary cirrhosis in rats by preventing mitochondrial oxidative stress. Hepatology 39(3), 711-720 (2004).
40. Mitchell C, Robin MA, Mayeuf A et al. Protection against hepatocyte mitochondrial dysfunction delays fbrosis progression in mice. Am J. Pathol. 175(5), 1929-1937 (2009).
41. Sanyal AJ, Chalasani N, Kowdley KV. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 362(18), 1675-1685 (2010).
42. Arseneau KO, Tamagawa H, Pizarro TT, Cominelli F. Innate and adaptive immune responses related to IBD pathogenesis. Curr. Gastroenterol. Rep. 9, 508-512 (2007).
43. Meneghin MD, Hogaboam C. Infectious disease, the innate immune response, and fbrosis. J. Clin. Invest. 117, 530-538 (2007).
44. Akira S, Takeda K. Toll-like receptor signalling. Nat. Rev. Immunol. 4(7), 499-511 (2004).
45. Otte JM, Rosenberg IM, Podolsky DK. Intestinal myofbroblasts in innate immune responses of the intestine. Gastroenterology 124(7), 1866-1878 (2003).
46. Coelho AL, Hogaboam CM, Kunkel SL. Chemokines provide the sustained infammatory bridge between innate and acquired immunity. Cytokine Growth Factor Rev. 16, 553-560 (2005).
47. Brun P, Castagliuolo I, Pinzani M, Palu G, Martines D. Exposure to bacterial cell wall products triggers an infammatory phenotype in hepatic stellate cells. Am. J. Physiol. Gastrointest. Liver Physiol. 289, G571-G578 (2005).
48. Brun P, Castagliuolo I, Di Leo V et al. Increased intestinal permeability in obese mice: new evidences in the pathogenesis of nonalcoholic steatohepatitis. Am. J. Physiol Gastrointest. Liver Physiol. 292, G518-G525 (2007).
49. Seki E, Brenner DA. Toll-like receptors and adaptor molecules in liver disease: update. Hepatology 48, 322-335 (2008).
50. Seki E, De Minicis S, Osterreicher CH et al. TLR4 enhances TGF-p signaling and hepatic fbrosis. Nat. Med. 13, 1324-1332 (2007).
51. Huang H, Shiffman ML, Friedman S et al. A 7 gene signature identifes the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology 46, 297-306 (2007).
52. Li Y, Chang M, Abar O et al. Multiple variants in toll-like receptor 4 gene modulate risk of liver fbrosis in Caucasians with chronic hepatitis C infection. J. Hepatol. 51, 750-757 (2009).
53. Watanabe A, Hashmi A, Gomes DA et al Apoptotic hepatocyte DNA inhibits hepatic stellate cell chemotaxis via toll like receptor 9. Hepatology 46, 1509-1518 (2007).
54. Gabele E, Muhlbauer M, Dorn C et al. Role of TLR9 in hepatic stellate cells and experimental liver fbrosis. Biochem. Biophys. Res. Commun. 376, 271-276 (2008).
55. Miura K, Kodama Y, Inokuchi S et al. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1p in mice. Gastroenterology DOI: 10.1053/j.gastro. 2010.03.052 (2010) (Epub ahead of print).
56. Mencin A, Kluwe J, Schwabe RF. Toll-like receptors as targets in chronic liver diseases. Gut 58, 704-720 (2009).
57. Gao B, Radaeva S, Park O. Liver natural killer and natural killer T cells: immunobiology and emerging roles in liver diseases. J. Leukoc. Biol. 86(3), 513-528 (2009).
58. Jeong WI, Park O, Radaeva S, Gao B. STAT1 inhibits liver fbrosis in mice by inhibiting stellate cell proliferation and stimulating NK cell cytotoxicity. Hepatology 44(6), 1441-1451 (2006).
59. Melhem A, Muhanna N, Bishara A et al Anti-fbrotic activity of NK cells in experimental liver injury through killing of activated HSC. J. Hepatol. 45(1), 60-71 (2006).
60. Jeong WI, Park O, Gao B. Abrogation of the antifbrotic effects of natural killer cells/interferon-y contributes to alcohol acceleration of liver fbrosis. Gastroenterology 134(1), 248-258 (2008).
61. Radaeva S, Sun R, Jaruga B, Nguyen VT, Tian Z, Gao B. Natural killer cells ameliorate liver fbrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners. Gastroenterology 130(2), 435-452 (2006).
62. Chen Y, Wei H, Sun R, Dong Z, Zhang J, Tian Z. Increased susceptibility to liver injury in hepatitis B virus transgenic mice involves NKG2D-ligand interaction and natural killer cells. Hepatology 46 (3), 706-715 (2007).
63. Safadi R, Zigmond E, Pappo O, Shalev Z, Ilan Y Amelioration of hepatic fbrosis via p-glucosylceramide mediated immune modulation is associated with altered CD8 and NKT lymphocyte distribution. Int. Immunol. 19, 1021-1029 (2007).
64. Kimura K, Nagaki M, Matsuura T, Moriwaki H, Kakimi K. Pathological role of CD44 on NKT cells in carbon tetrachloride-mediated liver injury. Hepatol. Res. 39, 93-105 (2009).
65. Park O, Jeong WI, Wang L et al. Diverse roles of invariant natural killer T cells in liver injury and fbrosis induced by carbon tetrachloride. Hepatology 49, 1683-1694 (2009).
66. Connolly MK, Bedrosian AS, Mallen-St Clair J et al. In liver fbrosis, dendritic cells govern hepatic infammation in mice via TNF-a. J. Clin. Invest. 119(11), 3213-3225 (2009).
67. Bataller R, Paik YH, Lindquist JN, Lemasters JJ, Brenner DA. Hepatitis C virus core and nonstructural proteins induce fbrogenic effects in hepatic stellate cells. Gastroenterology 126(2), 529-540 (2004).
68. Mazzocca A, Sciammetta SC, Carloni V et al. Binding of hepatitis C virus envelope protein E2 to CD81 up-regulates matrix metalloproteinase-2 in human hepatic stellate cells. J. Biol. Chem. 280(12), 11329-11339 (2005).
69. Bruno R, Galastri S, Sacchi P et al. The HIV envelope protein GP120 modulates the biology of human hepatic stellate cells: a link between HIV infection and liver fbrogenesis. Gut 59(4), 513-520 (2010).
70. Tilg H, Hotamisligil GS. Nonalcoholic fatty liver disease: cytokine-adipokine interplay and regulation of insulin resistance. Gastroenterology 131, 934-945 (2006).
71. Marra F, Aleff S, Bertolani C, Petrai I, Vizzutti F. Adipokines and liver fbrosis. Eur. Rev. Med. Pharmacol. Sci. 9(5), 279-284 (2005).
72. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 372, 425-432 (1994).
73. Potter JJ, Womack L, Mezey E, Anania FA. Transdifferentiation of rat hepatic stellate cells results in leptin expression. Biochem. Biophys. Res. Commun. 244, 178-182 (1998).
74. Ikejima K, Honda H, Yoshikawa M et al. Leptin augments infammatory and profbrogenic responses in the murine liver induced by hepatotoxic chemicals. Hepatology 34, 288-297 (2001).
75. Honda H, Ikejima K, Hirose M et al Leptin is required for fbrogenic responses induced by thioacetamide in the murine liver. Hepatology 36, 12-21 (2002).
76. Saxena NK, Ikeda K, Rockey DC, Friedman SL, Anania FA. Leptin in hepatic fbrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology 35, 762-771 (2002).
77. Ding X, Saxena NK, Lin S, Xu A, Srinivasan S, Anania FA. The roles of leptin and adiponectin: a novel paradigm in adipocytokine regulation of liver fbrosis and stellate cell biology. Am J. Pathol. 166, 1655-1669 (2005).
78. Leclercq IA, Farrell GC, Schriemer R, Robertson GR. Leptin is essential for the hepatic fbrogenic response to chronic liver injury. J. Hepatol. 37, 206-213 (2002).
79. Potter JJ, Mezey E. Leptin defciency reduces but does not eliminate the development of hepatic fbrosis in mice infected with Schistosoma mansoni. Liver 22, 173-177 (2002).
80. Bugianesi E, Manzini P, DAntico S et al Relative contribution of iron burden, HFE mutations, and insulin resistance to fbrosis in nonalcoholic fatty liver. Hepatology 39, 179-187 (2004). (Pubitemid 38461480)
81. Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J. Hepatol. 42, 132-138 (2005).
82. Steppan CM, Bailey ST, Bhat S et al. The hormone resistin links obesity to diabetes. Nature 409, 307-312 (2001).
83. Bertolani C, Sancho-Bru P, Failli P et al. Resistin as an intrahepatic cytokine: over expression during chronic injury and induction of proinfammatory actions in hepatic stellate cells. Am J. Pathol. 169(6), 2042-2053 (2006).
84. Matsuzawa Y. Therapy insight: adipocytokines in metabolic syndrome and related cardiovascular disease. Nat. Clin. Pract. Cardiovasc. Med. 3, 35-42 (2006).
85. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J. Clin. Invest. 112, 91-100 (2003).
86. Kamada Y, Tamura S, Kiso S et al Enhanced carbon tetrachloride-induced liver fbrosis in mice lacking adiponectin. Gastroenterology 125, 1796-1807 (2003).
87. Yamauchi T, Kamon J, Minokoshi Y et al Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med. 8, 1288-1295 (2002).
88. Hardie DG. Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology 144, 5179-5183 (2003).
89. Caligiuri A, Bertolani C, Guerra CT et al. Adenosine monophosphate- activated protein kinase modulates the activated phenotype of hepatic stellate cells. Hepatology 47(2), 668-676 (2008).
90. Caraceni P, Domenicali M, Giannone F, Bernardi M. The role of the endocannabinoid system in liver diseases. Best Pract. Res. Clin. Endocrinol. Metab. 23(1), 65-77 (2009).
91. Parfeniuk A, Flisiak R. Role of cannabinoids in chronic liver diseases. World J. Gastroenterol. 14(40), 6109-6114 (2008).
92. Siegmund SV, Shwabe RF. Endocannabinoids in the pathogenesis and treatment of liver fbrosis. Am. J. Physiol. Gastrointest. Liver Physiol. 294, G357-G362 (2008).
93. Teixeira-Clerc F, Julien B, Grenard P et al. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fbrosis. Nat. Med. 12, 671-676 (2006).
94. Julien B, Grenard P, Texeira-Clerc F et al. Antifbrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology 128, 742-755 (2005).
95. Munoz-Luque J, Ros J, Fernandez-Varo G et al. Regression of fbrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats. J. Pharmacol. Exp. Ther. 324, 475-483 (2008).
96. Hézode C, Zafrani ES, Roudot-Thoraval F et al. Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C. Gastroenterology 134(2), 432-439 (2008).
97. Duffeld JS, Forbes SJ, Constandinou CM et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J. Clin. Invest. 115, 56-65 (2005).
98. Fallowfeld JA, Mizuno M, Kendall TJ et al. Scar-associated macrophages are a major source of hepatic matrix metalloproteinase-13 and facilitate the resolution of murine hepatic fbrosis. J. Immunol. 178, 5288-5295 (2007).
99. Mitchell C, Couton D, Couty JP et al. Dual role of CCR2 in the constitution and the resolution of liver fbrosis in mice. Am. J. Pathol. 174, 1766-1775 (2009).
100. Pesce JT, Ramalingam TR, Mentink-Kane MM et al. Arginase-1-expressing macrophages suppress Th2 cytokine-driven infammation and fbrosis. PLoS Pathog. 5(4), e1000371 (2009).
101. Thompson RW, Pesce JT, Ramalingam T Cationic amino acid transporter-2 regulates immunity by modulating arginase activity. PLoS Pathog. 4(3), e1000023 (2008).
102. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat. Med. 6, 389-395 (2000).
103. Medina J, Arroyo AG, Sanchez-Madrid F, Moreno-Otero R. Angiogenesis in chronic infammatory liver disease. Hepatology 39, 1185-1195 (2004).
104. Cassiman D, Libbrecht L, Desmet V, Denef C, Roskams T Hepatic stellate cell/myofbroblast subpopulations in fbrotic human and rat livers. J. Hepatol 36, 200-209 (2002).
105. Corpechot C, Barbu V, Wendum D et al Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fbrogenesis in experimental cirrhosis. Hepatology 35, 1010-1021 (2002).
106. Yoshiji H, Kuriyama S, Yoshii J et al. Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fbrogenesis. Gut 52, 1347-1354 (2003).
107. Medina J, Caveda L, Sanz-Cameno P et al Hepatocyte growth factor activates endothelial pro-angiogenic mechanisms relevant in chronic hepatitis C-associated neoangiogenesis. J. Hepatol. 38, 660-667 (2003).
108. Shimoda K, Mori M, Shibuta K, Banner B, Barnard G. Vascular endothelial growth factor/vascular permeability factor mRNA expression in patients with chronic hepatitis C and hepatocellular carcinoma. Int. J. Oncol. 14, 353-359 (1999).
109. Medina J, Sanz-Cameno P, Garcia-Buey L, Martin-Vilchez S, Lopez-Cabrera M, Moreno-Otero R. Evidence of angiogenesis in primary biliary cirrhosis: an immunohistochemical descriptive study J. Hepatol. 42, 124-131 (2005).
110. DeLeve LD, Wang X, Hu L, McCuskey MK, McCuskey RS. Rat liver sinusoidal endothelial cell phenotype is maintained by paracrine and autocrine regulation. Am. J. Physiol. Gastrointest. Liver Physiol. 287, G757-G763 (2004).
111. Novo E, Cannito S, Zamara E et al Pro angiogenic cytokines as hypoxia-dependent factors stimulating migration of human hepatic stellate cells. Am. J. Pathol 170(6), 1942-1953 (2007).
112. Aleff S, Petrai I, Bertolani C et al. Upregulation of proinfammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatology 42, 1339-1348 (2005).
113. Ricard-Blum S, Bresson-Hadni S, Vuitton DA, Ville G, Grimaud JA. Hydroxypyridinium collagen cross-links in human liver fbrosis: study of alveolar echinococcosis. Hepatology 15, 599-602 (1992).
114. Hayasaka A, Ilda S, Suzuki N, Kondo F, Miyazaki M, Yonemitsu H. Pyridinoline collagen cross-links in patients with chronic viral hepatitis and cirrhosis. J. Hepatol. 24, 692-698 (1996).
115. Issa R, Zhou X, Constandinou CM et al. Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. Gastroenterology 126, 1795-1808 (2004).
116. Iredale JP. Models of liver fbrosis: exploring the dynamic nature of infammation and repair in a solid organ. J. Clin. Invest. 117(3), 539-548 (2007).
117. Mallet V, Gilgenkrantz H, Serpaggi J et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann. Intern. Med. 149(6), 399-403 (2008).